Q3 net sales grew +4% (cc ¹, +4% USD), with core operating income ¹ +10% (cc, +11% USD) Sales growth driven by priorit ...

MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...

Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapies Novartis advances strategy of focused portfolio and prioritized therapeutic ...

Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6 Approval ...

Novartis ranked #19 in TIME and Statista's World's Best Companies 2026, rising from #114, based on employee satisfaction, growth and sustainability.

“The clinically meaningful overall survival benefit observed in NATALEE underscores Kisqali as a standard of care for eligible patients and its foundational role in early breast cancer treatment,” ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Explore opportunities with Novartis below.

Afrique du Sud Albanie Algérie Allemagne Ancienne république yougoslave de Macédoine Argentine Arménie Australie Autriche Bahamas Barbade Belgique Bénin Bermudes Bolivie Bosnie-Herzégovine Brésil ...

. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...

Twenty-five years ago, Novartis pioneered a paradigm shift in cancer care with the introduction of the first tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), transforming it from a ...